Search

Mary J Tanga

from Santa Barbara, CA
Age ~72
Get Report
Also known as:
Mary Jean Tanga, Marie J Tanga, Marie R Tanga, Mary J Clayto, Mary Tinga, Mary J
Phone and address:
2314 Anacapa St, Santa Barbara, CA 93105
(650) 949-4959
Related to:
Clayton R Tanga, 76Marie J Tanga, 32
Connected to:
Krishna Y Tanga, 50Chris Tangalin, 51John V Tangalin, 53Tiffany Tanganco, 48Cristina N Tanganelli, 37Yvonne L Tangang, 42Jessica Tangar, 36Nicole L Tangara, 46Ana T Tangari, 49Cesar A Tangarife, 40

Mary Tanga Phones & Addresses

  • 2314 Anacapa St, Santa Barbara, CA 93105 (650) 949-4959
  • San Jose, CA
  • Redwood City, CA
  • Los Altos, CA
  • Eagle Creek, OR
  • Santa Clara, CA

Publications

Us Patents

Compounds For Activating Tgf-Beta Signaling

View page
US Patent:
20090143394, Jun 4, 2009
Filed:
Oct 10, 2008
Appl. No.:
12/249577
Inventors:
Anton Wyss-Coray - Stanford CA, US
Mary J. Tanga - Los Altos CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Stanford CA
International Classification:
A61K 31/496
C07D 403/04
C07D 409/12
A61K 31/4965
A61P 25/28
A61K 31/404
C07D 241/04
US Classification:
51425211, 544357, 548465, 544393, 514414, 51425503
Abstract:
Compositions and methods for treatment and prevention of disorders and conditions characterized by reduced TGF-β signaling are described.

Arsenical Fluorescent Agents And Assays

View page
US Patent:
20110229929, Sep 22, 2011
Filed:
Mar 21, 2011
Appl. No.:
13/053206
Inventors:
Laura Ellen Downs Beaulieu - Menlo Park CA, US
Mary J. Tanga - Menlo Park CA, US
International Classification:
C12Q 1/04
C07F 9/80
C07F 9/88
US Classification:
435 34, 549207, 544226, 544 64, 544 4, 546 3
Abstract:
The invention provides methods and compositions for labeling dithiol-containing analytes.

Compounds For Activating Tgf-Beta Signaling

View page
US Patent:
20120095000, Apr 19, 2012
Filed:
Dec 12, 2011
Appl. No.:
13/323679
Inventors:
Anton Wyss-Coray - Stanford CA, US
Mary J. Tanga - Los Altos CA, US
Assignee:
SRI International - Menlo Park CA
The Board of Trustees of the Leland Stanford Junior University - Stanford CA
International Classification:
A61K 31/5377
C07D 295/155
C07D 405/12
C07D 209/20
C07D 295/192
C07D 401/04
C07D 413/14
C07D 403/04
A61K 31/4045
A61K 31/495
A61K 31/4535
A61K 31/4525
A61K 31/445
A61K 31/496
A61K 31/4465
A61P 25/00
A61P 9/00
A61P 35/00
A61P 19/08
A61P 29/00
A61P 25/28
C07D 409/12
US Classification:
5142358, 548467, 544393, 546213, 546205, 546226, 544360, 544121, 544357, 514414, 51425503, 514419, 514326, 514319, 514330, 51425301, 514331
Abstract:
Compositions and methods for treatment and prevention of disorders and conditions characterized by reduced TGF-β signaling are described.

Use Of (2R, 6R)-Hydroxynorketamine, (S)-Dehydronorketamine And Other Stereoisomeric Dehydro And Hydroxylated Metabolites Of (R,S)-Ketamine In The Treatment Of Depression And Neuropathic Pain

View page
US Patent:
20200360393, Nov 19, 2020
Filed:
Jul 31, 2020
Appl. No.:
16/945163
Inventors:
- Bethesda MD, US
- Camden NJ, US
- Menlo Park CA, US
CARLOS A. ZARATE - Germantown MD, US
MARC C. TORJMAN - Southampton PA, US
MICHAEL E. GOLDBERG - Philadelphia PA, US
MARY J. TANGA - Los Altos CA, US
International Classification:
A61K 31/5375
C07C 225/20
C07C 237/04
C07D 295/108
C07D 295/112
C07C 229/48
C07C 237/20
C07D 295/15
C07D 295/155
A61K 31/137
A61K 31/165
A61K 31/222
A61K 31/24
A61K 31/265
A61K 31/4453
Abstract:
The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine , or other stereoisomeric dehydro or hydroxylated ketamine metabolite.(2R,6R)-HydroxynorketamineThe disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain synthetic pain disorder (CRPD) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.

Use Of (2R, 6R)-Hydroxynorketamine, (S)-Dehydronorketamine And Other Stereoisomeric Dehydro And Hydroxylated Metabolites Of (R,S)- Ketamine In The Treatment Of Depression And Neuropathic Pain

View page
US Patent:
20180098993, Apr 12, 2018
Filed:
Dec 8, 2017
Appl. No.:
15/836396
Inventors:
- Bethesda MD, US
- Camden NJ, US
- Menlo Park CA, US
CARLOS A. ZARATE - GERMANTOWN MD, US
MARC C. TORJMAN - SOUTHAMPTON PA, US
MICHAEL E. GOLDBERG - PHILADELPHIA PA, US
MARY J. TANGA - LOS ALTOS CA, US
International Classification:
A61K 31/5375
C07C 225/20
C07C 237/04
A61K 31/24
A61K 31/222
C07D 295/108
C07D 295/15
A61K 31/137
C07D 295/112
C07D 295/155
C07C 237/20
C07C 229/48
A61K 31/265
A61K 31/4453
A61K 31/165
Abstract:
The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite.The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain synthetic pain disorder (CRPD) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.

Use Of (2R, 6R)-Hydroxynorketamine, (S)-Dehydronorketamine And Other Stereoisomeric Dehydro And Hydroxylated Metabolites Of (R,S)- Ketamine In The Treatment Of Depression And Neuropathic Pain

View page
US Patent:
20170049780, Feb 23, 2017
Filed:
Nov 2, 2016
Appl. No.:
15/341784
Inventors:
- Bethesda MD, US
- Camden NJ, US
- Menlo Park CA, US
CARLOS A. ZARATE - GERMANTOWN MD, US
MARC C. TORJMAN - SOUTHAMPTON PA, US
MICHAEL E. GOLDBERG - PHILADELPHIA PA, US
MARY J. TANGA - LOS ALTOS CA, US
International Classification:
A61K 31/5375
A61K 31/222
A61K 31/265
A61K 31/4453
C07D 295/155
A61K 31/137
C07C 237/04
C07C 225/20
C07D 295/15
A61K 31/165
A61K 31/24
Abstract:
The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite.(2R,6R)-hydroxynorketamineThe disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain synthetic pain disorder (CRPD) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.

Benzyl Urea Derivatives For Activating Tgf-Beta Signaling

View page
US Patent:
20160039756, Feb 11, 2016
Filed:
Mar 14, 2014
Appl. No.:
14/776313
Inventors:
- Palo Alto CA, US
- Menlo Park CA, US
Mary Jean Tanga - Los Altos CA, US
Assignee:
The Board of Trustees of the Leladn Stanford Junior University - Palo Alto CA
International Classification:
C07D 211/26
A61K 31/452
A61K 31/4465
Abstract:
Compositions and methods for treatment and prevention of disorders and conditions characterized by reduced TGF-B signaling are described. In particular, the compositions and methods are useful for reducing or eliminating the pathologies associated with Alzheimer's disease. The compositions include urea derivatives containing a piperidine, piperidinium, or a piperidin-4-yl methyl; cycloalkyl, aryl, and fluorobenzyl moieties.

The Use Of (2R, 6R)-Hydroxynorketamine, (S)-Dehydronorketamine And Other Stereoisomeric Dehydro And Hydroxylated Metabolites Of (R,S)- Ketamine In The Treatment Of Depression And Neuropathic Pain

View page
US Patent:
20140296241, Oct 2, 2014
Filed:
Oct 15, 2012
Appl. No.:
14/351441
Inventors:
- Bethesda MD, US
- Camden NJ, US
Michel Bernier - Pikesville MD, US
Carlos A. Zarate - Germantown MD, US
Marc C. Torjman - Southampton PA, US
Michael E. Goldberg - Philadelphia PA, US
Mary J. Tanga - Los Altos CA, US
International Classification:
C07D 295/155
C07C 225/20
C07C 237/20
C07D 295/15
C07C 229/48
US Classification:
5142395, 514331, 514512, 514534, 514546, 514626, 514647, 544165, 546239, 558260, 560107, 560129, 564194, 564307
Abstract:
The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite. (2R,6R)-hydroxynorketamine The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain disorder (CRPS) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.
Control profile
Mary J Tanga from Santa Barbara, CA, age ~72 Get Report